WHITEHAWK THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $48.70 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $48.70K.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $43.60K.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $200.00K, a 84.62% decline from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.30M, a 30.00% increase from fiscal 2021.
- WHITEHAWK THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $1.00M, a 570.37% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.70K 10-Q · filed 2026-08-06 | $48.70K 10-Q · filed 2026-08-06 | $48.70K derived: sum of 3 quarters · filed 2026-08-06 | $48.70K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $43.60K 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $43.60K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $43.60K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $43.00K 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $31.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $31.00K derived: sum of 3 quarters · filed 2025-05-08 | $231.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $31.00K derived: sum of 2 quarters · filed 2025-03-28 | $231.00K derived: sum of 3 quarters · filed 2025-03-28 | $200.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $31.00K 10-Q · filed 2024-11-06 | $231.00K derived: sum of 2 quarters · filed 2024-11-06 | $200.00K 10-Q · filed 2024-11-06 | -$53.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-07 | $200.00K 10-Q · filed 2024-08-07 | -$84.00K derived: sum of 3 quarters · filed 2024-08-07 | -$39.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $16.00K 10-Q · filed 2024-05-08 | -$284.00K derived: sum of 2 quarters · filed 2024-05-08 | -$239.00K derived: sum of 3 quarters · filed 2024-05-08 | $761.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$255.00K derived: sum of 2 quarters · filed 2024-03-13 | $745.00K derived: sum of 3 quarters · filed 2024-03-13 | $1.30M 10-K · filed 2024-03-13 |
| 2022-09-30 | $45.00K 10-Q · filed 2023-11-08 | $1.04M derived: sum of 2 quarters · filed 2023-11-08 | $1.60M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-09 | $1.50M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $1.00M 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $149.17K 10-K · filed 2021-03-11 | |||
| 2018-12-31 | $139.11K 10-K · filed 2020-03-16 | |||
| 2017-12-31 | $92.54K 10-K · filed 2019-03-07 | |||
| 2016-12-31 | $20.34K 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |